GH vs IMTX: fair value comparison
Guardant Health, Inc. and Immatics N.V. · Updated 2026-10-19
GH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IMTX reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, GH currently ranks higher by quality score.
| GH | IMTX | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $158.60 | $8.44 |
| 12-month range | $69.35–$187.22 | $6.73–$11.87 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #101 of 301 Healthcare | #102 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: GH fair value analysis · IMTX fair value analysis